Efficacy of vemurafenib in hairy-cell leukemia

New England Journal of Medicine

Volumn 370, Issue 3, 2014, Pages 286-288

  Samuel, Jesvin ^a   Macip, Salvador ^a   Dyer, Martin J S ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CD103 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; VEMURAFENIB;

CELL DEATH; CELL SURVIVAL; CELL VIABILITY; DRUG EFFICACY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME REPRESSION; FLOW CYTOMETRY; GENE MUTATION; HAIRY CELL LEUKEMIA; HUMAN; IMMUNOBLOTTING; LETTER; LEUKEMIA CELL; LEUKEMIA REMISSION; PANCYTOPENIA; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 84892621038     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1310849     Document Type: Letter

References (5)

1. Tiacci E, Trifonov V, Schiavoni G, et al. BRAF mutations in hairy-cell leukemia. N Engl J Med 2011;364:2305-15.
2. Follows GA, Sims H, Bloxham DM, et al. Rapid response of biallelic BRAF V600E mutated hairy cell leukaemia to low dose vemurafenib. Br J Haematol 2013;161:150-3.
3. Dietrich S, Glimm H, Andrulis M, von Kalle C, Ho AD, Zenz T. BRAF inhibition in refractory hairy-cell leukemia. N Engl J Med 2012;366:2038-40.
4. Dietrich S, Hullein J, Hundemer M, et al. Continued response off treatment after BRAF inhibition in refractory hairy cell leukemia. J Clin Oncol 2013;31(19):e300-e303.
5. Dyer MJ, Vogler M, Samuel J, et al. Precision medicines for B-cell leukaemias and lymphomas; progress and potential pitfalls. Br J Haematol 2013;160:725-33.